CD33 and acute myeloid leukemia: We also utilized CyTOF analysis to determine protein expression perturbations in PD, CD34 + , phenotypically characterized, AML stem-progenitor cells with mtNPM1 and FLT3-TKD, i.e., exhibiting high expressions of CLEC12A, CD123, CD244, CD90 and CD33, but low expression of CD11b, following treatment with SNDX-50469 plus OTX015 compared to SNDX-50469 alone [41–43].